Erick Gamelin - 01 Mar 2026 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role: Chief Development Officer
Signature: /s/ Adam D. Levy, Attorney-in-Fact
Issuer symbol: ACRV
Transactions as of: 01 Mar 2026
Net transactions value: $0
Form type: 4
Filing time: 03 Mar 2026, 16:17:45 UTC
Previous filing: 18 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Gamelin Erick	Chief Development Officer	C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN	/s/ Adam D. Levy, Attorney-in-Fact	03 Mar 2026	0001950551

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACRV	Stock Option (Right to Buy)	Award	$0	+94,946		$0.000000	94,946	01 Mar 2026	Common Stock	94,946	$1.51	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.